Skip to main navigation Skip to search Skip to main content

A Phase II Multicenter Double-Blind Placebo-Controlled Study of Ethyl Pyruvate in High-Risk Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

  • Elliott Bennett-Guerrero
  • , Madhav Swaminathan
  • , Alina M. Grigore
  • , Gary W. Roach
  • , Laura G. Aberle
  • , Jeffrey M. Johnston
  • , Mitchell P. Fink
  • Duke University
  • St. Luke's Episcopal Health System
  • Kaiser Permanente
  • Critical Therapeutics Inc
  • University of Pittsburgh

Research output: Contribution to journal › Article › peer-review

77 Scopus citations

Abstract

Objective: Ethyl pyruvate (EP) is an investigational drug that has been shown to protect animals in several models of critical illness including myocardial or mesenteric ischemia/reperfusion injury, sepsis, and hemorrhagic shock. The purpose of this study was to assess the safety of EP administration to patients undergoing higher-risk cardiac surgery and to obtain preliminary efficacy data for the prevention of single and multisystem organ dysfunction. Design: Double-blind, randomized, placebo-controlled study. Setting: Thirteen US hospitals. Participants: High-risk (Parsonnet risk score >15) patients undergoing coronary artery bypass graft and/or cardiac valvular surgery with cardiopulmonary bypass. Interventions: Subjects were randomized to placebo or EP (7,500 mg administered intravenously starting after the induction of general anesthesia followed by 5 more doses of 7,500 mg administered every 6 hours). The mean body weight (83 kg), corresponding to a dose of 90 mg/kg at each of the 6 dosing intervals, exceeds the dose of 40 mg/kg shown to be effective in many animal models. Measurements and Main Results: The primary composite endpoint consisted of any of the following occurring within 28 days postoperatively: death, mechanical ventilation >48 hours postoperatively, acute renal injury/failure using the established RIFLE criteria, or need for vasoconstrictors >48 hours postoperatively. One hundred two patients were studied (placebo n = 53 and EP n = 49). No statistically significant differences were observed between groups with regard to clinical parameters or markers of systemic inflammation. Conclusion: Despite positive results in numerous animal models, the administration of EP does not appear to confer any benefit to cardiac surgical patients undergoing CPB.

Original languageEnglish
Pages (from-to)324-329
Number of pages6
JournalJournal of Cardiothoracic and Vascular Anesthesia
Volume23
Issue number3
DOIs
StatePublished - Jun 2009

Keywords

  • cardiac surgery
  • cardiopulmonary bypass
  • ethyl pyruvate
  • human
  • phase II

Fingerprint

Dive into the research topics of 'A Phase II Multicenter Double-Blind Placebo-Controlled Study of Ethyl Pyruvate in High-Risk Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass'. Together they form a unique fingerprint.

Cite this